| Primary Identifier | MGI:2450567 | Allele Type | Transgenic |
| Attribute String | Inserted expressed sequence | Gene | Tg(CD4-HIV)F26622Pjo |
| Strain of Origin | (C57BL/6 x C3H)F2 | Is Recombinase | false |
| Is Wild Type | false |
| description | Transgenic founder lines F26132, F26605, and F26622 were established. The latency of disease was reflective of the level of transgene expression. Founders F26605 and F26622 developed a disease phenotype similar to that observed in MutA trangenics. The high-expressing founder F26605 died early at less than 2 months of age, whereas moderate-expressing founder F26622 died at a later time. Low-expressing founder F26132 did not exhibit a phenotype. |
| molecularNote | Mouse CD4 enhancer sequences, the human CD4 promoter, 8.8 kb of HIV sequences, and an SV40 polyadenylation signal was used for the transgene. The enhancer and promoter sequences were used to drive expression in CD4+ T cells and cells of the dendritic/macrophage lineage. The HIV sequence contained a stop oligo insertion at nucleotide 6400 of the env gene. Northern blot analysis showed high transgene expression in the thymus, moderate expression in lymph nodes, and weak expression in kidneys, lungs, intestines, and liver. |
